Skip to main content

Advertisement

SpringerLink
Log in

Ofatumumab regimens in chronic lymphocytic leukemia: a meta-analysis

  • Review Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Ofatumumab’s therapeutic impact on patients with chronic lymphocytic leukemia (CLL) has been the subject of increasing clinical research. However, in recent years, no studies have yet provided a pooled assessment of the treatment effect of ofatumumab vs. non-ofatumumab regimens. Therefore, we conducted a progression meta-analysis to evaluate the efficacy of ofatumumab-based treatment in CLL patients using data from clinical studies. Relevant publications from PubMed, Web of Science and ClinicalTrials.gov were searched. The efficacy outcomes were progression-free survival (PFS) and overall survival (OS). The articles reviewed in the mentioned databases and matching the specified keywords were searched until January 2023. The pooled efficacy analysis showed that there was a significant difference in PFS [hazard ratios (HR) = 0.62, 95% confidence interval (CI) = 0.52–0.74] and no significant difference in OS (HR = 0.86, 95% CI = 0.71–1.03) between ofatumumab-based therapy and non-ofatumumab therapy. Our analysis showed the pooled efficacy for PFS was statistically significantly improved with ofatumumab-based treatments for CLL compared with other groups. Also, ofatumumab had no statistically significant improvement in the OS of patients with CLL. Thus, ofatumumab-based therapies for CLL patients could be improved by other combinational-based regimens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Data availability

Datasets are available through the corresponding author upon reasonable request.

Abbreviations

CLL:

Chronic lymphocytic leukemia.

PFS:

Progression-free survival

OS:

Overall survival

MESH:

Medical Subject Headings

WoS:

Web of Science

PRISMA:

Preferred Reporting Items for Systematic Reviews and Meta-Analysis

CONSORT:

Consolidated Standards of Reporting Trials

References

  1. Chiorazzi N, Chen SS, Rai KR (2021) Chronic Lymphocytic Leukemia. Cold Spring Harb Perspect Med 11(2):a035220

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Cohen JA, Bomben R, Pozzo F, Tissino E, Härzschel A, Hartmann TN et al (2020) An updated perspective on current prognostic and predictive biomarkers in chronic lymphocytic leukemia in the context of chemoimmunotherapy and novel targeted therapy. Cancers 12(4):894

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Yao Y, Lin X, Li F, Jin J, Wang H (2022) The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019. Biomed Eng Online 21(1):4

    Article  PubMed  PubMed Central  Google Scholar 

  4. Dores GM, Anderson WF, Curtis RE, Landgren O, Ostroumova E, Bluhm EC et al (2007) Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol 139(5):809–819

    Article  PubMed  Google Scholar 

  5. Weide R, Feiten S, Chakupurakal G, Friesenhahn V, Kleboth K, Köppler H et al (2020) Survival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care 1995–2017. Leuk Lymphoma 61(3):557–566

    Article  CAS  PubMed  Google Scholar 

  6. Evans J, Ziebland S, Pettitt AR (2012) Incurable, invisible and inconclusive: watchful waiting for chronic lymphocytic leukaemia and implications for doctor-patient communication. Eur J Cancer Care (Engl) 21(1):67–77

    Article  CAS  PubMed  Google Scholar 

  7. Messori A, Fadda V, Maratea D, Trippoli S (2015) First-line treatments for chronic lymphocytic leukaemia: interpreting efficacy data by network meta-analysis. Ann Hematol 94(6):1003–1009

    Article  CAS  PubMed  Google Scholar 

  8. Zhang J, Lu X, Li J et al (2022) Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma. Biomark Res 10(1):17

    Article  PubMed  PubMed Central  Google Scholar 

  9. Lemery SJ, Zhang J, Rothmann MD, Yang J, Earp J, Zhao H et al (2010) U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res 16(17):4331–8

    Article  CAS  PubMed  Google Scholar 

  10. Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A et al (2010) Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 28(10):1749–1755

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Österborg A, Udvardy M, Zaritskey A, Andersson PO, Grosicki S, Mazur G et al (2016) Phase III, randomized study of ofatumumab versus physicians’ choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leuk Lymphoma 57(9):2037–2046

    Article  PubMed  Google Scholar 

  12. van Oers MH, Kuliczkowski K, Smolej L, Petrini M, Offner F, Grosicki S et al (2015) Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. Lancet Oncol 16(13):1370–1379

    Article  PubMed  Google Scholar 

  13. Robak T, Warzocha K, GovindBabu K, Kulyaba Y, Kuliczkowski K, Abdulkadyrov K et al (2017) Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. Leuk Lymphoma 58(5):1084–1093

    Article  CAS  PubMed  Google Scholar 

  14. van Oers M, Smolej L, Petrini M, Offner F, Grosicki S, Levin MD et al (2019) Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer J 9(12):98

    Article  PubMed  PubMed Central  Google Scholar 

  15. Rupp T, Zuckerman D (2017) Quality of life, overall survival, and costs of cancer drugs approved based on surrogate endpoints. JAMA Intern Med 177(2):276–277

    Article  PubMed  Google Scholar 

  16. Kim C, Prasad V (2015) Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals. JAMA Intern Med 175(12):1992–1994

    Article  PubMed  Google Scholar 

  17. Jones JA, Robak T, Brown JR, Awan FT, Badoux X, Coutre S et al (2017) Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol 4(3):e114–e126

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

By Student Research Committee, Faculty of Allied Medicine, Kerman University of Medical Sciences, Kerman.

Author information

Authors and Affiliations

  1. Department of Hematology and Medical Laboratory Sciences, Faculty of Allied Medicine, Kerman University of Medical Sciences, Kerman, Iran

    Muhammad Hossein Ashoub

  2. Student Research Committee, Faculty of Allied Medicine, Kerman University of Medical Sciences, Kerman, Iran

    Amirreza Naseri & Parisa Mohammadi

  3. Cellular and Molecular Research Center, Gerash University of Medical Sciences, Gerash, Iran

    Masoud Mohammadi

Authors
  1. Muhammad Hossein Ashoub
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amirreza Naseri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Parisa Mohammadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masoud Mohammadi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MHA and AN and PM contributed to the design, MM statistical analysis, participated in most of the study steps. MM and MHA and AN and PM prepared the manuscript. MHA and AN and PM and MM assisted in designing the study, and helped in the, interpretation of the study. All authors have read and approved the content of the manuscript.

Corresponding author

Correspondence to Masoud Mohammadi.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ashoub, M.H., Naseri, A., Mohammadi, P. et al. Ofatumumab regimens in chronic lymphocytic leukemia: a meta-analysis. Ann Hematol 102, 1301–1306 (2023). https://doi.org/10.1007/s00277-023-05246-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-023-05246-x

Keywords

Search

Navigation